Enzalutamide (Xtandi®): A Comprehensive Clinical and Pharmacological Monograph

Section 1: Introduction and Overview

Executive Summary

Enzalutamide is a pivotal second-generation, nonsteroidal antiandrogen (NSAA) that has fundamentally altered the therapeutic paradigm for patients with advanced prostate cancer.[1] As a potent and highly specific androgen receptor (AR) signaling inhibitor, its mechanism of action is multifaceted, involving the blockade of androgen binding, prevention of AR nuclear translocation, and impairment of AR-DNA interaction.[1] This comprehensive inhibition of the primary oncogenic driver in prostate cancer has translated into remarkable clinical efficacy across a broad spectrum of disease states. Enzalutamide has demonstrated significant improvements in survival and delayed disease progression in metastatic and non-metastatic settings, as well as in both castration-sensitive and castration-resistant prostate cancer.[1] Marketed under the brand name Xtandi®, it is recognized as a cornerstone therapy, typically administered orally once daily in conjunction with androgen deprivation therapy (ADT).[1] Its clinical utility is, however, balanced by a distinct and significant safety profile characterized by fatigue, cardiovascular events, and an increased risk of falls and fractures, which necessitates proactive and vigilant clinical management.[5]

Classification and Significance

Enzalutamide is classified as a small molecule androgen receptor inhibitor.[7] Its development represented a significant evolution from first-generation NSAAs, such as bicalutamide, by offering substantially higher binding affinity for the AR—approximately eight times greater—and a more complete blockade of the AR signaling pathway without the partial agonist activity that limited the efficacy of its predecessors.[1] This mechanistic superiority has established enzalutamide as a "second-generation" agent, capable of inducing apoptosis in prostate cancer cells and demonstrating efficacy in settings where older agents have failed.[7] Its profound impact on the management of prostate cancer is underscored by its inclusion on the World Health Organization's List of Essential Medicines for malignant neoplasms of the prostate.[2]

The trajectory of enzalutamide's clinical development and regulatory approvals reflects a major strategic shift in oncology. The drug's journey began with an initial approval in 2012 for patients in the most advanced, refractory setting: metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy.[4] Success in this population led to its systematic evaluation and subsequent approval in progressively earlier stages of the disease. This includes pre-chemotherapy mCRPC, non-metastatic CRPC (where the goal shifted from prolonging life to delaying the onset of metastasis), and ultimately into castration-sensitive disease states.[4] This timeline demonstrates a clear and successful trend of moving a highly effective agent to earlier lines of therapy. The underlying principle is that targeting the primary driver of prostate cancer—the AR pathway—more potently and earlier in the disease course can yield deeper and more durable responses, delaying progression to more aggressive, resistant states and ultimately improving long-term outcomes like overall survival. This represents a fundamental paradigm shift from the historical approach of reserving the most potent therapies for later, more desperate stages of the disease.

Commercial and Regulatory Context

Enzalutamide, originally developed under the code MDV3100, is marketed globally under the brand name Xtandi® by Astellas Pharma and Pfizer, following a collaboration established in 2009.[1] It has secured regulatory approval from major health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, for a range of prostate cancer indications.[4]

Section 2: Physicochemical Properties and Formulations

A precise understanding of a drug's physicochemical properties is fundamental to its clinical pharmacology and application. Enzalutamide is a well-characterized small molecule with specific identifiers, chemical features, and formulations that dictate its behavior in vivo.

Systematic Identification

To ensure unambiguous reference, enzalutamide is cataloged under multiple standard identifiers. Its developmental code was MDV3100 (also cited as MDV-3100 or HC-1119).[2] The systematic IUPAC chemical name is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.[1] Key database identifiers are summarized in Table 1.

Chemical and Physical Properties

Enzalutamide possesses a molecular formula of C21​H16​F4​N4​O2​S and a molecular weight of 464.44 g/mol.[9] Structurally, it is a complex thiohydantoin derivative, belonging to several chemical classes, including benzamides, imidazolidinones, nitriles, and organofluorine compounds.[2] It presents as a white to off-white, crystalline, non-hygroscopic solid.[15]

A critical property influencing its formulation and pharmacokinetics is its solubility. Enzalutamide is practically insoluble in water, with an aqueous solubility of ≤2.0 μg/mL across the physiological pH range.[16] However, it is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF).[14] This combination of low aqueous solubility and high membrane permeability across Caco-2 monolayers classifies enzalutamide as a Biopharmaceutics Classification System (BCS) Class 2 drug.[17] The BCS Class 2 designation is a defining physicochemical characteristic that directly informs its formulation science, oral bioavailability, and potential for food-drug interactions. Drugs with low solubility often require advanced formulation technologies to improve their dissolution rate and subsequent absorption. The initial formulation of enzalutamide as a liquid-filled soft gelatin capsule containing a solution in caprylocaproyl macrogolglycerides is a classic example of a lipid-based strategy designed to enhance the solubilization of a lipophilic, poorly soluble compound in the gastrointestinal tract.[16] For many BCS Class 2 drugs, administration with food, particularly high-fat meals, can increase absorption by stimulating bile flow and enhancing drug solubilization. However, dedicated clinical studies for enzalutamide have demonstrated that while food may alter the rate of absorption (Cmax), it does not have a clinically significant effect on the overall extent of absorption (AUC).[18] This indicates that the formulation is sufficiently robust to overcome major food-related absorption variability, a desirable clinical characteristic that simplifies administration instructions and improves convenience for patients.[6]

Formulations and Strengths

Enzalutamide is available for oral administration in two primary dosage forms: liquid-filled soft gelatin capsules and film-coated tablets.[6] The capsules are available in a 40 mg strength, while the tablets are available in both 40 mg and 80 mg strengths.[2] The development of a tablet formulation subsequent to the initial capsule likely represents a product life-cycle management strategy aimed at improving patient convenience, potentially by reducing the pill burden from four capsules to two tablets for the standard daily dose. Regardless of the formulation, administration instructions are consistent: the capsules or tablets must be swallowed whole with water and must not be chewed, crushed, dissolved, or opened, to ensure the integrity of the formulation and predictable drug release.[20]

---

Table 1: Drug Identification and Physicochemical Properties

Property	Value	Source(s)
Generic Name	Enzalutamide	1
Brand Name	Xtandi®	1
DrugBank ID	DB08899	1
CAS Number	915087-33-1	1
IUPAC Name	4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide	1
Molecular Formula	C21​H16​F4​N4​O2​S	9
Molecular Weight	464.44 g/mol	9
Chemical Class	Thiohydantoin derivative, Nonsteroidal Antiandrogen (NSAA)	1
Physical Appearance	White to off-white crystalline solid	15
Solubility	Practically insoluble in water; Soluble in DMSO, DMF	14
BCS Class	Class 2 (Low Solubility, High Permeability)	17
Available Formulations	Liquid-filled soft gelatin capsules; Film-coated tablets	6
Available Strengths	Capsules: 40 mg; Tablets: 40 mg, 80 mg	6

---

Section 3: Clinical Pharmacology

The clinical efficacy of enzalutamide is rooted in its potent and distinct pharmacological properties. Its mechanism of action represents a more complete inhibition of the androgen receptor signaling pathway compared to its predecessors, and its pharmacodynamic effects on the endocrine system and central nervous system are critical to understanding both its therapeutic benefit and its side effect profile.

3.1 Mechanism of Action: A Multi-Pronged Attack on AR Signaling

Enzalutamide is a potent, selective, and silent antagonist of the androgen receptor (AR), the primary driver of prostate cancer growth.[1] Its designation as a second-generation NSAA stems from its significantly enhanced efficacy over first-generation agents like bicalutamide, which is attributable to both a higher binding affinity and a more comprehensive mechanism of action that lacks the partial agonist activity seen with older drugs.[1]

The superiority of enzalutamide is not merely a quantitative improvement in potency but a qualitative advancement in its mechanism. While first-generation agents primarily act as competitive antagonists at the ligand-binding site, they can exhibit partial agonist properties and may not fully prevent the nuclear translocation of the AR.[1] Enzalutamide overcomes these limitations through a multi-step inhibitory process that effectively shuts down the entire downstream signaling cascade, which explains its efficacy in castration-resistant states where the AR pathway is often hyperactivated.[3] This multifaceted mechanism includes:

1. Competitive Inhibition of Ligand Binding: Enzalutamide potently and competitively blocks the binding of the natural androgens—testosterone and its more active metabolite, dihydrotestosterone (DHT)—to the AR's ligand-binding domain.[3] Its binding affinity is remarkably high, being 5- to 8-fold greater than that of bicalutamide and only 2- to 3-fold lower than that of DHT itself, underscoring its ability to effectively outcompete the endogenous ligands.[1]
2. Inhibition of Nuclear Translocation: In a crucial departure from first-generation NSAAs, enzalutamide actively prevents the translocation of the ligand-bound AR from the cell cytoplasm into the nucleus.[1] By trapping the receptor in the cytoplasm, it prevents the AR from accessing its genomic targets, a key step in androgen-mediated gene expression.
3. Impairment of DNA Binding and Coactivator Recruitment: For any residual AR that might enter the nucleus, enzalutamide further disrupts its function by impairing the receptor's ability to bind to specific DNA sequences known as Androgen Response Elements (AREs) on target genes.[1] Furthermore, it inhibits the recruitment of essential coactivator proteins that are necessary for the assembly of the transcriptional machinery.[1]

This comprehensive blockade of the AR signaling pathway culminates in decreased proliferation and increased apoptosis (programmed cell death) of prostate cancer cells, leading to tumor regression in preclinical models and robust clinical activity, even in cell lines resistant to bicalutamide.[7]

3.2 Pharmacodynamics

The pharmacodynamic effects of enzalutamide extend beyond the tumor cell to systemic hormonal and neurological systems.

Hormonal Effects and the Necessity of Castration: A key pharmacodynamic consequence of enzalutamide's potent AR blockade is a paradoxical surge in the very hormones it is designed to inhibit when used as a monotherapy. By blocking ARs in the pituitary gland, enzalutamide disrupts the negative feedback loop that testosterone normally exerts to suppress the secretion of luteinizing hormone (LH).[1] Without this feedback, the pituitary releases more LH, which in turn stimulates the testes to produce more testosterone. Clinical studies of enzalutamide monotherapy have documented dramatic increases in circulating levels of LH (over 300%), testosterone (over 100%), DHT (over 50%), and estradiol (over 70%).[1] This physiological response underscores the absolute necessity of co-administering enzalutamide with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy in most clinical settings. This concomitant medical or surgical castration suppresses testicular androgen production, preventing a hormonal surge that could potentially overcome the drug's receptor blockade and fuel tumor growth.[5]

Exposure-Response Relationship: The standard 160 mg once-daily dose has been shown to be effective across a wide range of patient exposures. An exposure-response analysis from a pivotal phase III trial found that all quartiles of patients, grouped by their steady-state trough drug concentrations, derived a uniform survival benefit relative to placebo. No specific plasma concentration threshold was identified above which efficacy was improved, suggesting that the 160 mg dose achieves sufficient AR saturation and clinical benefit for the vast majority of patients.[17]

Central Nervous System Effects: Enzalutamide and its active metabolite are known to cross the blood-brain barrier.[16] The drug's primary neurological toxicity, a lowered seizure threshold, is believed to result from off-target inhibition of the GABA-gated chloride channel in the central nervous system.[1] This mechanism is also thought to contribute to other observed CNS-related side effects, such as anxiety, insomnia, and cognitive disturbances.[1]

Section 4: Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of enzalutamide is characterized by robust oral absorption, extensive distribution, primary hepatic metabolism via a key cytochrome P450 enzyme, and a notably long elimination half-life for both the parent drug and its active metabolite. These properties are central to its dosing schedule and drug interaction profile.

4.1 Absorption and Distribution

Absorption: Following oral administration, enzalutamide is well absorbed, with an estimated absolute bioavailability of at least 84.2%.[16] Peak plasma concentrations (Tmax) are typically reached within 1 to 2 hours after dosing.[16] A key clinical advantage is the lack of a significant food effect; while a high-fat meal can delay absorption, it does not meaningfully alter the overall extent of exposure (AUC), allowing for convenient administration with or without food.[17]

Distribution: Enzalutamide exhibits extensive extravascular distribution, as indicated by its large apparent volume of distribution (V/F) of approximately 110 L.[16] Both enzalutamide and its principal active metabolite, N-desmethyl enzalutamide, are capable of crossing the blood-brain barrier, a property consistent with the observed central nervous system side effects.[16] The drug is highly bound to plasma proteins, with protein binding measuring 97-98% for enzalutamide and 95% for its metabolites.[18] It is not a substrate for the major efflux drug transporters P-glycoprotein (P-gp) or Breast Cancer Resistance Protein (BCRP).[16]

4.2 Metabolism and Elimination

Metabolism: Enzalutamide is cleared from the body almost exclusively through extensive hepatic metabolism.[7] The primary metabolic pathway involves oxidation mediated by the cytochrome P450 enzyme

CYP2C8. The enzyme CYP3A4/5 plays a secondary, lesser role in its metabolism.[16] This heavy reliance on CYP2C8 for clearance is the basis for its most critical drug-drug interactions.

Metabolites: Two major metabolites are found in human plasma:

• N-desmethyl enzalutamide (M2): This is a pharmacologically active metabolite that exhibits in vitro potency similar to the parent compound. At steady state, its plasma concentrations are approximately equal to those of enzalutamide, meaning it contributes substantially to the overall therapeutic effect of the drug.[6]
• Carboxylic acid metabolite (M1): This metabolite is pharmacologically inactive.[7]

Elimination and Half-Life: The products of hepatic metabolism are eliminated primarily via renal excretion. Following a radiolabeled dose, 71% is recovered in the urine (mostly as the inactive carboxylic acid metabolite) and 14% is recovered in the feces.[7]

The elimination half-lives of both enzalutamide and its active metabolite are notably long. This characteristic is a double-edged sword: it allows for convenient once-daily dosing but also means that adverse effects, once they develop, can be slow to resolve after dose interruption. The time required for a drug to be eliminated from the body is approximately five half-lives; for the active metabolite of enzalutamide, this could be longer than 40 days. This slow washout period is a critical consideration for clinicians managing toxicity, as patients must be counseled that side effects like fatigue may not resolve quickly after stopping the drug.

• The mean terminal half-life (t1/2) for enzalutamide is 5.8 days.[7]
• The active metabolite, N-desmethyl enzalutamide, has an even longer mean terminal half-life of approximately 7.8 to 8.6 days.[7]

4.3 Pharmacokinetics and Dosing Implications

Steady State and Accumulation: The long half-life dictates that steady-state plasma concentrations are not achieved until approximately day 28 of continuous dosing.[17] This implies that the full therapeutic effect, and potentially the full extent of side effects, may not become apparent for the first month of treatment. With once-daily administration, enzalutamide accumulates approximately 8.3-fold relative to a single dose.[16]

Special Populations:

• Hepatic Impairment: Clinical studies have shown that no dose adjustment is necessary for patients with mild, moderate, or even severe (Child-Pugh Class A, B, or C) hepatic impairment.[18]
• Renal Impairment: Similarly, no dose adjustment is required for patients with mild to moderate renal impairment (Creatinine Clearance [CrCl] ≥ 30 mL/min). The pharmacokinetics of enzalutamide have not been formally evaluated in patients with severe renal impairment (CrCl < 30 mL/min) or end-stage renal disease requiring dialysis.[18]

The primary reliance on CYP2C8 for metabolism makes enzalutamide uniquely vulnerable to strong inhibitors of this specific enzyme, representing a critical and potentially overlooked interaction pathway. While many clinicians are highly attuned to interactions involving the more ubiquitous CYP3A4 enzyme, the central role of CYP2C8 for enzalutamide clearance is its Achilles' heel. The FDA label and European prescribing information provide stern warnings and specific dose-reduction mandates when co-administration with strong CYP2C8 inhibitors (e.g., gemfibrozil) is unavoidable.[21] Quantitative data show that gemfibrozil can increase the systemic exposure (AUC) of enzalutamide by over 300%, a massive increase that would almost certainly elevate the risk of toxicity.[26] This underscores the critical need for heightened vigilance and thorough medication review by a pharmacist to identify and manage this specific interaction.

---

Table 2: Summary of Key Pharmacokinetic Parameters of Enzalutamide and N-desmethyl Enzalutamide

Parameter	Enzalutamide	N-desmethyl Enzalutamide	Source(s)
Bioavailability	≥84.2%	N/A (Metabolite)	16
Tmax (Time to Peak)	1–2 hours	Slower to form	16
Food Effect on AUC	No clinically significant effect	No clinically significant effect	18
Protein Binding	97–98%	95%	18
Volume of Distribution (V/F)	~110 L	N/A	16
Primary Metabolic Enzyme	CYP2C8 (major), CYP3A4/5 (minor)	N/A (Metabolite)	16
Half-life (t1/2)	5.8 days	7.8–8.6 days	7
Time to Steady State	~28 days	~28 days	17
Primary Route of Elimination	Hepatic metabolism, renal excretion of metabolites	Hepatic metabolism, renal excretion of metabolites	7

---

Section 5: Clinical Efficacy Across the Prostate Cancer Spectrum

The clinical development of enzalutamide has been marked by a series of successful pivotal trials, systematically establishing its efficacy across a remarkably broad range of advanced prostate cancer disease states. This consistent and robust evidence base validates the central role of potent AR signaling inhibition as a therapeutic strategy throughout the disease continuum. In nearly every clinically relevant stage of advanced prostate cancer, enzalutamide has demonstrated a statistically significant and clinically meaningful improvement in major endpoints such as overall survival (OS), metastasis-free survival (MFS), or radiographic progression-free survival (rPFS). This consistent success suggests that even as the cancer evolves to become castration-resistant or metastasizes, its dependence on the AR signaling pathway remains a critical and exploitable vulnerability. This positions enzalutamide not as a niche drug for a specific stage, but as a foundational agent that can be deployed at multiple points in a patient's treatment journey.

5.1 Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Post-Chemotherapy (AFFIRM Trial): Enzalutamide's initial FDA approval was secured based on the results of the AFFIRM trial, which enrolled 1,199 men with mCRPC whose disease had progressed after treatment with docetaxel chemotherapy.[4] The trial demonstrated a significant OS benefit, which was the primary endpoint. Beyond survival, a pre-planned secondary analysis of AFFIRM revealed critical benefits related to bone health. In this population, where bone metastases are nearly ubiquitous, enzalutamide significantly reduced the risk of skeletal-related events (SREs)—such as radiation to the bone or spinal cord compression—by 31% compared to placebo. It also significantly delayed the median time to the first SRE to 16.7 months versus 13.3 months for placebo.[28] Furthermore, treatment with enzalutamide led to significant improvements in pain control and overall health-related quality of life (HRQoL).[28]

Chemotherapy-Naïve (PREVAIL Trial): Following its success in the post-chemotherapy setting, the indication was expanded based on the PREVAIL trial, which studied 1,717 men with chemotherapy-naïve mCRPC.[11] PREVAIL demonstrated powerful efficacy, with enzalutamide significantly reducing the risk of death by 29% (Hazard Ratio 0.71) and the risk of radiographic progression or death by an impressive 83% (HR 0.17) compared to placebo.[7] Final analysis reported a median OS of 35.3 months for the enzalutamide arm versus 31.3 months for the placebo arm.[29] A key practical benefit was a 17-month delay in the median time to initiation of cytotoxic chemotherapy for patients receiving enzalutamide, preserving quality of life by postponing more toxic treatments.[13]

5.2 Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

PROSPER Trial: Enzalutamide's role expanded into the pre-metastatic setting with the PROSPER trial. This study randomized 1,401 men with NM-CRPC and a rapidly rising prostate-specific antigen (PSA) level (doubling time ≤ 10 months), a population at high risk for developing metastases.[12] The primary endpoint was metastasis-free survival (MFS). Enzalutamide demonstrated a profound benefit, nearly tripling the median MFS from 14.7 months with placebo to 36.6 months (HR 0.29), representing a 71% reduction in the risk of metastasis or death.[12] Importantly, this MFS benefit translated into a significant overall survival advantage in the final analysis, with a median OS of 67.0 months for enzalutamide versus 56.3 months for placebo (HR 0.73).[29]

5.3 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ARCHES and ENZAMET Trials: The efficacy of enzalutamide was next proven in the castration-sensitive setting, where the goal is to intensify initial ADT.

• The ARCHES trial randomized 1,150 men with mCSPC to receive either enzalutamide plus ADT or placebo plus ADT.[4] The combination therapy resulted in a 61% lower risk of radiographic progression or death compared to ADT alone.[29] The final OS analysis confirmed a significant survival benefit, with a 34% reduction in the risk of death. At the 5-year mark, the survival rate was 66% for men in the combination arm compared to 53% for those receiving ADT and placebo.[29]
• The ENZAMET trial, an international academic-led study, also evaluated enzalutamide in 1,125 men with mHSPC, but with a flexible design that allowed for concurrent use of docetaxel at the physician's discretion.[32] The study confirmed a significant OS benefit for the addition of enzalutamide to standard of care (testosterone suppression with or without docetaxel). Long-term follow-up at a median of 98 months (over 8 years) continued to show a substantial OS advantage, with median survival of 95 months for the enzalutamide group versus 70 months for the control group (HR 0.73).[34]

The ENZAMET trial's design provides nuanced data that helps deconstruct the benefits of "triplet" versus "doublet" therapy. While the overall trial was positive for enzalutamide, exploratory subgroup analyses suggested that the magnitude of the OS benefit was less pronounced in patients who also received docetaxel (HR 0.82) compared to the overall cohort (HR 0.70).[35] The benefit appeared greatest in patients with low-volume disease who did not receive chemotherapy. This suggests that for patients with low-volume mCSPC, potent hormonal therapy (ADT plus enzalutamide) may be a highly effective and sufficient strategy. Conversely, for patients with high-volume disease, the data supports the use of triplet therapy (ADT plus docetaxel plus enzalutamide) to achieve the best outcomes.[36] This challenges a "one-size-fits-all" approach to treatment intensification and supports a more personalized strategy based on disease volume and patient fitness for chemotherapy.

5.4 Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) with High-Risk Biochemical Recurrence (BCR)

EMBARK Trial: The most recent indication expansion was based on the EMBARK trial, which targeted a very early disease state: men with high-risk BCR following definitive local therapy (prostatectomy or radiation) who were not yet castrate-resistant.[4] The trial had three arms: enzalutamide plus leuprolide (combination), enzalutamide monotherapy, and placebo plus leuprolide (ADT alone). Both enzalutamide-containing arms demonstrated superior MFS compared to ADT alone. The combination arm showed a 58% lower risk of metastasis or death, while the monotherapy arm showed a 37% lower risk.[29] The combination therapy also resulted in a statistically significant improvement in overall survival.[37] These results established a new standard of care for this high-risk population, offering a way to intervene early to prevent or delay metastatic progression.

---

Table 3: Summary of Pivotal Phase 3 Clinical Trials for Enzalutamide

Trial Name (Acronym)	Indication	Patient Population	N	Treatment Arms	Primary Endpoint	Key Result (HR [95% CI]; p-value)	Key Secondary Endpoint (OS)	Source(s)
AFFIRM	mCRPC	Post-docetaxel	1,199	Enzalutamide vs. Placebo	Overall Survival (OS)	HR 0.63 [0.53, 0.75]; p<0.001	N/A (Primary)	4
PREVAIL	mCRPC	Chemotherapy-naïve	1,717	Enzalutamide vs. Placebo	Co-primary: rPFS & OS	rPFS: HR 0.19 [0.15, 0.23]; p<0.001	OS: HR 0.71 [0.60, 0.84]; p<0.001	4
PROSPER	NM-CRPC	High-risk (PSADT ≤10 mo)	1,401	Enzalutamide vs. Placebo	Metastasis-Free Survival (MFS)	HR 0.29 [0.24, 0.35]; p<0.001	OS: HR 0.73 [0.61, 0.89]; p=0.001	4
ARCHES	mCSPC	Metastatic, hormone-sensitive	1,150	Enzalutamide + ADT vs. Placebo + ADT	Radiographic PFS (rPFS)	HR 0.39 [0.30, 0.50]; p<0.001	OS: HR 0.66 [0.53, 0.81]; p<0.001	4
ENZAMET	mCSPC	Metastatic, hormone-sensitive	1,125	Enzalutamide + SoC vs. NSAA + SoC	Overall Survival (OS)	HR 0.70 [0.58, 0.84]; p<0.001	N/A (Primary)	4
EMBARK	nmCSPC	High-risk BCR	1,068	Enza + ADT vs. Enza mono vs. ADT	Metastasis-Free Survival (MFS)	Enza+ADT vs ADT: HR 0.42 [0.30, 0.61]; p<0.001	OS (Enza+ADT): HR 0.59 [0.39, 0.89]; p=0.01	4

---

Section 6: Safety Profile and Tolerability

While enzalutamide has demonstrated profound efficacy, its use is associated with a distinct and clinically significant safety profile. A thorough understanding of its adverse reactions, warnings, and precautions is essential for appropriate patient selection, counseling, and proactive management to maintain quality of life and ensure treatment adherence.

Most Common Adverse Reactions

Across pivotal clinical trials, a consistent pattern of common adverse reactions has emerged. The most frequently reported events (generally occurring in ≥10% of patients) are systemic, musculoskeletal, and gastrointestinal in nature. These include asthenia/fatigue, which is particularly prominent and reported in up to 51% of patients, back pain, musculoskeletal pain, arthralgia, hot flush, diarrhea, peripheral edema, headache, and hypertension.[5] Other common side effects include decreased appetite, dizziness, constipation, and upper respiratory tract infections.[5]

Warnings and Precautions

The FDA-approved prescribing information for enzalutamide includes several important warnings and precautions highlighting the most serious potential risks of therapy.

Seizure: Enzalutamide is associated with a risk of seizure, as it can lower the seizure threshold.[1] In pooled data from randomized trials, seizures occurred in 0.6% of patients receiving enzalutamide.[30] The risk is elevated in patients with predisposing factors, such as a prior history of seizure, traumatic brain injury, stroke, brain tumors, or concomitant use of medications known to lower the seizure threshold; in a study dedicated to this higher-risk population, 2.2% of patients experienced a seizure.[1] Patients must be counseled on this risk and advised to avoid activities where a sudden loss of consciousness could cause serious harm to themselves or others. If a patient develops a seizure during treatment, enzalutamide should be permanently discontinued.[5]

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES, a neurological disorder characterized by rapidly evolving symptoms including seizure, headache, lethargy, confusion, and visual disturbances, have been reported.[20] A diagnosis requires confirmation by brain imaging (preferably MRI), and the condition necessitates permanent discontinuation of enzalutamide.[5]

Ischemic Heart Disease: Clinical trials have demonstrated an increased risk of ischemic heart disease. Pooled data from five randomized, placebo-controlled studies showed that ischemic heart disease occurred more commonly in patients on the enzalutamide arm compared to placebo (3.5% vs 2.0%).[30] The incidence of severe (Grade 3-4) ischemic events was 1.8% with enzalutamide versus 1.1% with placebo, and these events led to death in 0.4% of patients on enzalutamide compared to 0.1% on placebo.[5] This risk necessitates careful monitoring for signs and symptoms of ischemic heart disease and optimization of cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia.[21]

Falls and Fractures: The safety profile of enzalutamide reveals a clinically significant cascade of related toxicities. The drug's direct CNS effects, particularly fatigue and dizziness, act as a primary catalyst for an increased risk of falls. In an elderly patient population already predisposed to bone density loss from concomitant ADT, these falls translate into a high rate of fractures. This is not three separate side effects, but one interconnected geriatric syndrome that requires a multi-pronged management approach. Across clinical trials, falls were reported in 11-13% of patients treated with enzalutamide compared to 4% with placebo, and fractures occurred in 10% of patients versus 4% with placebo.[6] This elevated risk requires clinicians to evaluate patients for fall and fracture risk at baseline and throughout treatment, and to consider the use of bone-targeted agents (e.g., denosumab, bisphosphonates) according to established treatment guidelines.[5]

Hypersensitivity: Hypersensitivity reactions, including edema of the face, tongue, or lips, have been observed.[21] More severe reactions, such as pharyngeal edema, have been reported in post-marketing cases. Patients should be advised to discontinue the drug and seek immediate medical care if symptoms of hypersensitivity occur. Serious reactions warrant permanent discontinuation of enzalutamide.[21]

Embryo-Fetal Toxicity: Enzalutamide can cause fetal harm and loss of pregnancy when administered to a pregnant female. Although not indicated for use in women, this warning is critical for patient counseling. Males with female partners of reproductive potential must be advised to use effective contraception (e.g., a condom plus another effective method) during treatment and for 3 months following the final dose.[5]

Dysphagia or Choking: A specific warning has been added regarding the potential for swallowing problems or choking, which may be related to the size of the oral formulations.[20]

Other Clinically Relevant Adverse Events

Beyond the formal warnings, several other adverse events are common and can significantly impact quality of life. These include cognitive and psychiatric effects such as memory impairment, anxiety, and visual hallucinations [1];

endocrine effects like gynecomastia and breast tenderness [1]; and

hematologic effects such as neutropenia.[1]

The choice between enzalutamide and other novel hormonal agents like abiraterone may be influenced by a patient's specific comorbidities, particularly cardiovascular health. While both drugs carry cardiovascular risks, their profiles differ. Enzalutamide is more directly associated with hypertension and ischemic events.[43] In contrast, abiraterone's risk is often mediated by a secondary mineralocorticoid excess (causing hypertension, hypokalemia, and fluid retention), which necessitates co-administration with prednisone to mitigate.[45] Real-world data and meta-analyses suggest that abiraterone may be associated with a higher short-term risk of major adverse cardiovascular events (MACE) and heart failure compared to enzalutamide.[46] This distinction allows for a more personalized risk-benefit assessment; for instance, a patient with pre-existing heart failure might be a poorer candidate for abiraterone, whereas a patient with a history of seizures would be a poorer candidate for enzalutamide.

---

Table 4: Adverse Reactions Reported in ≥5% of Patients in Pooled Clinical Trials

System Organ Class	Adverse Reaction	Frequency Category	Enzalutamide (%)	Placebo (%)	Source(s)
General Disorders	Asthenia/Fatigue	Very Common	51	46	7
	Peripheral Edema	Very Common	15	12	7
Musculoskeletal	Back Pain	Very Common	29	26	7
	Arthralgia	Very Common	21	17	7
	Musculoskeletal Pain	Very Common	15	12	7
	Muscular Weakness	Common	9	6	6
Nervous System	Headache	Very Common	12	6	5
	Dizziness/Vertigo	Very Common	12	7	5
	Falls	Very Common	13	5	6
	Cognitive Impairment	Common	5	2	1
	Seizure	Rare	0.6	0	1
Gastrointestinal	Diarrhea	Very Common	22	18	1
	Constipation	Very Common	23	18	39
Vascular	Hot Flush	Very Common	20	10	5
	Hypertension	Very Common	14	5	6
Metabolism	Decreased Appetite	Very Common	19	16	5
Psychiatric	Insomnia	Common	9	6	1
	Anxiety	Common	6	4	1
Reproductive System	Gynecomastia	Common	N/A	N/A	1
Note: Frequencies and percentages are drawn from various pooled analyses and individual trial reports; direct comparison may vary based on the specific study population and duration. "N/A" indicates data was not presented in a comparable format in the provided sources.

---

Section 7: Clinical Management of Key Adverse Events

Effective management of enzalutamide-associated adverse events is crucial for maintaining patient quality of life, ensuring treatment adherence, and maximizing the drug's therapeutic potential. Strategies often involve a combination of non-pharmacologic interventions, supportive care medications, and, when necessary, dose modification.

7.1 Neurological and Cognitive Effects

Fatigue (Asthenia): As the most common adverse event, fatigue requires a proactive management approach.[39] Non-pharmacologic strategies are the first line of defense and include educating the patient on the importance of pacing daily activities, incorporating gentle physical exercise (which has been shown to paradoxically improve cancer-related fatigue), and ensuring adequate rest and sleep hygiene.[49] Pharmacologic interventions with stimulants have shown inconsistent results in the setting of ADT-induced fatigue.[51]

A critical management strategy for severe or intolerable fatigue is dose modification. Clinical data show that fatigue is a primary driver for dose reduction (affecting 13% of patients) and treatment discontinuation (6%).[48] This has spurred research into whether lower doses can maintain efficacy while improving tolerability. Emerging data on dose reduction represents a significant evolution in the clinical use of enzalutamide, shifting from a "one-dose-fits-all" model to a more personalized approach. Pharmacokinetic studies suggest that AR saturation may be achieved at doses lower than the standard 160 mg.[52] The NCT03927391 trial provided direct evidence for this, demonstrating that a reduced starting dose of 120 mg daily significantly lessened the severity of CNS side effects, including fatigue and cognitive decline, compared to the 160 mg dose. Crucially, this improvement in tolerability was achieved without compromising efficacy, as patients on the lower dose maintained therapeutic plasma concentrations and equivalent PSA response rates.[52] For frail, elderly patients or those experiencing significant CNS toxicity, a proactive dose reduction to 120 mg is an evidence-based strategy that can improve quality of life and help keep them on this life-prolonging therapy.

Seizure Risk: Management is centered on prevention through careful patient selection and education. The drug should be avoided in patients with a significant history of seizures or other major predisposing factors.[5] All patients must be counseled on the risk and advised to avoid activities where a sudden loss of consciousness could be dangerous (e.g., driving, operating heavy machinery).[5] If a seizure occurs, enzalutamide must be permanently discontinued.[5]

7.2 Cardiovascular Risk Management

Hypertension: Regular blood pressure monitoring is essential for all patients starting enzalutamide.[49] Management of new or worsening hypertension should follow standard clinical guidelines, incorporating lifestyle modifications (e.g., low-sodium diet, exercise) and the initiation or titration of antihypertensive medications.[50]

Ischemic Heart Disease: Proactive management involves monitoring for signs and symptoms (e.g., chest pain, dyspnea on exertion) and aggressively managing underlying cardiovascular risk factors, including hypertension, diabetes, and dyslipidemia.[21] For patients who develop severe (Grade 3-4) ischemic heart disease, treatment with enzalutamide should be discontinued.[21]

7.3 Musculoskeletal Health

Falls and Fractures: Mitigating the high risk of falls and fractures requires a comprehensive, multidisciplinary approach.

• Risk Assessment: All patients, particularly the elderly, should be assessed for fall and fracture risk at baseline and periodically during treatment.[5]
• Fall Prevention: Patients should receive counseling on fall prevention strategies. This includes recommendations for home safety modifications (e.g., removing trip hazards, ensuring good lighting), referral to physical therapy for strength and balance training, and wearing appropriate, supportive footwear.[49]
• Bone Health Management: Given that patients are on long-term ADT, which induces bone loss, bone health must be actively managed. Baseline and periodic bone mineral density screening (e.g., DEXA scan) should be considered.[49] The use of bone-targeted agents, such as bisphosphonates or denosumab, should be implemented according to established clinical guidelines for preventing skeletal complications in men on ADT.[5] The importance of this was highlighted in the PEACE III trial, where mandating the use of bone-protecting agents was shown to reduce the fracture rate when enzalutamide was combined with radium-223.[54]

7.4 Endocrine and Systemic Effects

Gynecomastia: The development of breast enlargement and tenderness is a common and often distressing side effect, particularly when enzalutamide is used as a monotherapy.[1] The underlying pathophysiology is an imbalance between estrogen and androgen effects on breast tissue, where the potent AR blockade by enzalutamide allows unopposed estrogenic stimulation.[56]

• Management: Prophylaxis is the most effective strategy. While much of the evidence comes from studies with older antiandrogens like bicalutamide, the principles are now being applied to enzalutamide monotherapy. Effective prophylactic options include a short course of low-dose radiation therapy directed at the breast buds or the use of the selective estrogen receptor modulator (SERM) tamoxifen.[56] For patients who develop established, symptomatic gynecomastia that is refractory to other measures, surgical excision (subcutaneous mastectomy) remains the gold standard treatment.[56]

Hot Flushes: This is a very common side effect of androgen deprivation. Management typically begins with lifestyle modifications, such as wearing layered clothing, maintaining a cool ambient temperature, and avoiding potential triggers like caffeine and alcohol.[49] For severe or bothersome hot flushes, various pharmacologic interventions can be considered.

Section 8: Dosage, Administration, and Drug Interactions

The safe and effective use of enzalutamide requires strict adherence to recommended dosing, administration guidelines, and careful management of its complex drug interaction profile.

Recommended Dosage and Administration

The standard recommended dosage of enzalutamide is 160 mg administered orally once daily.[5] This dose can be administered as four 40 mg capsules or two 80 mg tablets.[61] It should be taken at approximately the same time each day, but can be taken with or without food.[40] Patients must be instructed to swallow the capsules or tablets whole with water and to not chew, crush, dissolve, or open them.[21]

For most approved indications—specifically mCRPC, nmCRPC, and mCSPC—patients receiving enzalutamide should also receive a concomitant GnRH analog or have undergone a bilateral orchiectomy to maintain medical or surgical castration.[5] For the indication of nmCSPC with high-risk BCR, treatment may be administered with or without a GnRH analog, and intermittent therapy may be considered.[22]

Dose Modifications

The prescribing information provides clear guidelines for dose modification in response to toxicity or drug interactions.

• For Adverse Reactions: If a patient experiences a Grade 3 or higher, or an otherwise intolerable adverse reaction, enzalutamide should be withheld for one week or until symptoms improve to Grade 2 or less. Treatment can then be resumed at the same dose (160 mg) or at a reduced dose of 120 mg or 80 mg daily if warranted.[6]
• For Drug Interactions:
• Concomitant Strong CYP2C8 Inhibitors: The co-administration of strong CYP2C8 inhibitors (e.g., gemfibrozil) should be avoided. If this is not possible, the enzalutamide dosage must be reduced to 80 mg once daily.[21]
• Concomitant Strong CYP3A4 Inducers: The co-administration of strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) should be avoided. If unavoidable, the enzalutamide dosage should be increased from 160 mg to 240 mg once daily.[21]

Drug-Drug Interactions

The drug interaction profile of enzalutamide is complex and bidirectional. It is not only affected by other drugs that modulate its metabolism but also significantly affects the metabolism of a wide range of other medications. This makes a thorough medication review by a clinical pharmacist an essential safety measure before initiating and during therapy.

Enzalutamide as a Victim of Interactions: As detailed previously, enzalutamide is a substrate of CYP2C8 (major) and CYP3A4 (minor). Its plasma concentrations can be significantly increased by strong CYP2C8 inhibitors, necessitating a dose reduction, or decreased by strong CYP3A4 inducers, necessitating a dose increase.[21]

Enzalutamide as a Perpetrator of Interactions: Enzalutamide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19.[2] This means it can accelerate the metabolism of many co-administered drugs that are substrates for these enzymes, potentially leading to decreased plasma concentrations and loss of therapeutic efficacy.

• Clinical Implications: Co-administration of enzalutamide with drugs that have a narrow therapeutic index and are substrates of these enzymes should be avoided if possible. Examples of affected drug classes include, but are not limited to, certain anticoagulants (e.g., warfarin, a CYP2C9 substrate), antiplatelet agents (e.g., clopidogrel, a CYP2C19 substrate), immunosuppressants, statins, and some chemotherapeutic agents. If co-administration is necessary, dose adjustments of the substrate drug and/or enhanced clinical or laboratory monitoring (e.g., frequent INR monitoring for patients on warfarin) is required.[21]

---

Table 5: Clinically Significant Drug-Drug Interactions with Enzalutamide

Part A: Drugs Affecting Enzalutamide Concentrations
Interacting Drug Class	Example Drug(s)	Effect on Enzalutamide	Recommended Management	Source(s)
Strong CYP2C8 Inhibitors	Gemfibrozil	↑ Enzalutamide levels, ↑ risk of toxicity	Avoid co-administration. If unavoidable, reduce enzalutamide dose to 80 mg/day.	21
Strong CYP3A4 Inducers	Rifampin, Carbamazepine, Phenytoin, St. John's Wort	↓ Enzalutamide levels, ↓ efficacy	Avoid co-administration. If unavoidable, increase enzalutamide dose to 240 mg/day.	21
Part B: Enzalutamide Affecting Other Drug Concentrations
Affected Drug Class (Enzyme Substrate)	Example Drug(s)	Effect on Substrate	Recommended Management	Source(s)
CYP3A4 Substrates	Midazolam, certain statins (e.g., simvastatin), certain calcium channel blockers, certain immunosuppressants (e.g., tacrolimus)	↓ Substrate levels, ↓ efficacy	Avoid co-administration if possible. If necessary, may require dose increase of the substrate drug with careful monitoring.	21
CYP2C9 Substrates	Warfarin, Phenytoin	↓ Substrate levels, ↓ efficacy	Avoid co-administration if possible. For warfarin, conduct additional INR monitoring and adjust warfarin dose as needed.	21
CYP2C19 Substrates	Omeprazole, Clopidogrel	↓ Substrate levels, ↓ efficacy	Avoid co-administration if possible. Consider alternative agents that are not metabolized by CYP2C19.	21

---

Section 9: Regulatory and Development History

The regulatory history of enzalutamide is a compelling case study in successful, evidence-driven drug development. It illustrates a strategic and systematic approach to expanding a drug's utility, moving from a late-stage, refractory setting to an early-stage, preventative one, thereby transforming the standard of care at multiple points along the prostate cancer treatment continuum.

Development and Commercialization

Enzalutamide was originally developed under the code MDV3100 by the biopharmaceutical company Medivation, Inc. In October 2009, Medivation entered into a major global collaboration agreement with Astellas Pharma Inc. to jointly develop and commercialize the drug.[13] Under the agreement, the companies collaborate on a comprehensive development program and jointly commercialize the product, now branded as Xtandi®, in the United States. Astellas holds the responsibility for manufacturing and for regulatory filings and commercialization outside the U.S..[13] Following Pfizer's acquisition of Medivation, the drug is now co-marketed by Astellas and Pfizer.[63]

FDA Approval Timeline

The U.S. Food and Drug Administration (FDA) has granted a series of approvals for enzalutamide, each expanding its indicated patient population based on the results of landmark clinical trials.

• August 31, 2012: The initial FDA approval was granted for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received docetaxel chemotherapy. This approval was based on the significant overall survival benefit demonstrated in the AFFIRM trial.[4]
• September 10, 2014: The indication was expanded to include the treatment of chemotherapy-naïve patients with mCRPC. This broader approval, which removed the requirement for prior chemotherapy, was based on the robust efficacy data from the PREVAIL trial.[4]
• July 13, 2018: Enzalutamide received approval for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). This marked a significant shift, as the therapeutic goal became the prevention or delay of metastasis. The approval was based on the strong metastasis-free survival data from the PROSPER trial.[4]
• December 16, 2019: The drug's utility was further expanded into the castration-sensitive setting, with an approval for patients with metastatic castration-sensitive prostate cancer (mCSPC). This was based on the results of the ARCHES trial, which showed that adding enzalutamide to ADT was superior to ADT alone.[4]
• June 20, 2023: A new combination therapy was approved. Enzalutamide in combination with the PARP inhibitor talazoparib was approved for adult patients with homologous recombination repair (HRR) gene-mutated mCRPC.[7]
• November 16, 2023: The most recent approval extended enzalutamide's use to an even earlier disease state: non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). This indication was based on the positive outcomes of the EMBARK trial.[4]

International Approvals

Enzalutamide has also been approved by other major regulatory bodies worldwide. The European Medicines Agency (EMA) granted its initial marketing authorization on June 21, 2013, which has been followed by subsequent expansions of the indication to align with its proven efficacy in various prostate cancer settings.[4] Approvals were also secured from Health Canada (May 29, 2013) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) (March 24, 2014).[4]

Section 10: Emerging Research and Future Directions

The clinical development of enzalutamide continues to evolve, with current research focused on two primary frontiers: creating novel combination therapies to overcome resistance and further improve outcomes, and exploring its utility in new clinical settings, including earlier stages of prostate cancer and other malignancies. This research landscape reflects a broader trend in oncology where the goal is to attack cancer from multiple angles simultaneously to achieve deeper, more durable responses and delay the emergence of resistance.

10.1 Novel Combination Therapies

While enzalutamide is a highly effective monotherapy (with ADT), resistance inevitably develops. The most active area of current research, therefore, involves combining it with agents that have different mechanisms of action.

• PARP Inhibitors: The combination of enzalutamide with the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib is now FDA-approved for patients with mCRPC harboring homologous recombination repair (HRR) gene mutations.[7] This is based on the principle of synthetic lethality, where inhibiting the AR pathway with enzalutamide may increase reliance on PARP for DNA repair, making cancer cells exquisitely sensitive to PARP inhibition.
• Radioligand Therapy (RLT): The ENZA-p trial (NCT04419402) is a landmark phase II study investigating the combination of enzalutamide with 177Lutetium-PSMA-617, a radioligand therapy that delivers targeted radiation to cells expressing prostate-specific membrane antigen (PSMA).[65] The rationale is synergistic; preclinical evidence suggests that AR blockade with enzalutamide upregulates the expression of PSMA on cancer cells, potentially enhancing the targeting and efficacy of Lu-PSMA.[66] Early results have been highly promising, showing that the combination significantly improved PSA progression-free survival (13.0 vs 7.8 months) and demonstrated a striking overall survival advantage (median OS 34 vs 26 months) with a manageable safety profile.[68]
• Antibody-Drug Conjugates (ADCs): The NCT05011188 trial is a Phase 1b/2 study evaluating enzalutamide in combination with FOR46 (FG-3246), an ADC that targets the CD46 receptor and delivers a potent cytotoxic payload (MMAE).[70] The trial is enrolling mCRPC patients who have progressed after abiraterone.[70] Preclinical models suggested enhanced tumor-killing activity with the combination.[72] Positive interim data from the Phase 1b portion showed an encouraging median radiographic PFS of 10.2 months and an acceptable safety profile, validating further investigation in the Phase 2 portion.[72]

10.2 Expansion into New Indications

Earlier Stages of Prostate Cancer: The ENACT trial (NCT02799745) explored the use of enzalutamide in a preventative setting for men with low- or intermediate-risk localized prostate cancer who were undergoing active surveillance (AS).[74] The results of this phase II study perfectly illustrate the therapeutic index dilemma of moving effective but potentially toxic therapies into earlier, less-lethal disease states. The trial demonstrated that one year of enzalutamide monotherapy significantly reduced the risk of pathological or therapeutic disease progression by 46% compared to AS alone.[75] However, this delay in progression came at the cost of a significant side effect burden, including fatigue in 55% of patients and gynecomastia in 37%.[76] This raises a critical clinical question: is a delay in progression worth the guaranteed toxicity and impact on quality of life in a population where the primary goal of AS is to

avoid treatment and its associated side effects? For now, these findings suggest enzalutamide is unlikely to become a standard of care in the AS population, but they open the door for future research into lower, better-tolerated doses or intermittent therapy schedules in this setting.

Other Malignancies: The utility of enzalutamide is also being investigated beyond prostate cancer. Since some breast cancers express the androgen receptor, a phase II trial (NCT01889238) was conducted to evaluate the safety and efficacy of enzalutamide in patients with advanced, AR-positive, triple-negative breast cancer (TNBC), a subtype with limited targeted therapy options.[7]

Section 11: Expert Synthesis and Conclusion

Enzalutamide has unequivocally established itself as a highly potent, second-generation androgen receptor signaling inhibitor and a cornerstone of modern therapy for advanced prostate cancer. Its clinical value is supported by a wealth of high-level evidence from a series of landmark clinical trials that have systematically proven its efficacy across the entire disease continuum. From delaying the onset of metastases in non-metastatic disease to significantly extending overall survival in metastatic, castration-sensitive, and castration-resistant settings, enzalutamide consistently delivers clinically meaningful benefits.

Its current position in the therapeutic armamentarium is that of a foundational agent. The choice between enzalutamide and other novel hormonal agents, such as abiraterone or the newer ARPIs darolutamide and apalutamide, is increasingly driven by a careful, individualized assessment of the patient's specific clinical scenario. This includes consideration of disease characteristics (e.g., metastatic volume), prior therapies, and, critically, the patient's comorbidities and tolerance for specific side effect profiles. The distinct toxicities of enzalutamide—dominated by a clinically significant fatigue-fall-fracture cascade, cardiovascular risks, and neurological effects like seizure potential—must be weighed against the mineralocorticoid-related and hepatic toxicities of other agents. Proactive, vigilant management of these adverse events is paramount to maximizing the benefit of enzalutamide. The emerging evidence supporting dose reduction as a viable strategy to mitigate CNS toxicity without compromising efficacy represents a key evolution in its clinical application, allowing for a more personalized approach that can improve quality of life and treatment persistence.

The future trajectory of enzalutamide is firmly rooted in rational combination therapies. While it will remain a powerful agent in its approved indications, the most exciting frontiers involve its use as a synergistic backbone for novel treatments. The promising data from trials combining enzalutamide with radioligand therapy (ENZA-p), PARP inhibitors, and antibody-drug conjugates (FOR46) signal a clear path forward. These combinations aim to attack prostate cancer through multiple, complementary mechanisms, with the goal of overcoming intrinsic and acquired resistance, deepening therapeutic responses, and further extending survival for patients. As our understanding of prostate cancer biology and resistance pathways continues to grow, enzalutamide is poised to remain a central component of increasingly effective and personalized treatment regimens for years to come.

Works cited

1. Enzalutamide - Wikipedia, accessed July 11, 2025, https://en.wikipedia.org/wiki/Enzalutamide
2. Enzalutamide | C21H16F4N4O2S | CID 15951529 - PubChem, accessed July 11, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Enzalutamide
3. Evidence for the efficacy of enzalutamide in postchemotherapy, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3721441/
4. Enzalutamide (Xtandi) | HemOnc.org - A Hematology Oncology Wiki, accessed July 11, 2025, https://hemonc.org/wiki/Enzalutamide_(Xtandi)
5. XTANDI (enzalutamide) capsules - accessdata.fda.gov, accessed July 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203415s014lbl.pdf
6. This label may not be the latest approved by FDA. For current ..., accessed July 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203415s018,213674s005lbl.pdf
7. Enzalutamide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 11, 2025, https://go.drugbank.com/drugs/DB08899
8. en.wikipedia.org, accessed July 11, 2025, https://en.wikipedia.org/wiki/Enzalutamide#:~:text=Enzalutamide%20is%20an%20antiandrogen%2C%20and,and%20elsewhere%20in%20the%20body.
9. Enzalutamide | 99.99%(HPLC) | In Stock | Androgen Receptor antagonist, accessed July 11, 2025, https://www.selleckchem.com/products/mdv3100.html
10. Xtandi (enzalutamide) FDA Approval History - Drugs.com, accessed July 11, 2025, https://www.drugs.com/history/xtandi.html
11. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer - PubMed Central, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4524760/
12. FDA approves enzalutamide for castration-resistant prostate cancer, accessed July 11, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancer
13. U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer - the Astellas US Newsroom, accessed July 11, 2025, https://newsroom.astellas.us/news-releases?item=137065
14. Enzalutamide (MDV 3100, CAS Number: 915087-33-1) | Cayman Chemical, accessed July 11, 2025, https://www.caymanchem.com/product/11596/enzalutamide
15. Enzalutamide | Non-steroidal antiandrogen - Focus Biomolecules, accessed July 11, 2025, https://focusbiomolecules.com/enzalutamide-non-steroidal-antiandrogen/
16. Enzalutamide - Therapeutic Goods Administration (TGA), accessed July 11, 2025, https://www.tga.gov.au/sites/default/files/auspar-enzalutamide-160323-pi.docx
17. Clinical Pharmacokinetic Studies of Enzalutamide - PMC, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4580721/
18. enzalutamide - Cancer Care Ontario | Cancer Care Ontario, accessed July 11, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/44321
19. Clinical Pharmacokinetic Studies of Enzalutamide - PubMed, accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/25917876/
20. XTANDI® (enzalutamide) | Advanced Prostate Cancer Treatment, accessed July 11, 2025, https://www.xtandi.com/
21. XTANDI® (enzalutamide) capsules, for oral use - accessdata.fda.gov, accessed July 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203415s024,213674s012lbl.pdf
22. Xtandi Dosage Guide - Drugs.com, accessed July 11, 2025, https://www.drugs.com/dosage/xtandi.html
23. What is the mechanism of Enzalutamide?, accessed July 11, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-enzalutamide
24. Enzalutamide | Prostate Cancer UK, accessed July 11, 2025, https://prostatecanceruk.org/prostate-information-and-support/treatments/enzalutamide
25. enzalutamide | Cancer Care Ontario, accessed July 11, 2025, https://www.cancercareontario.ca/sites/ccocancercare/files/enzalutamide.pdf
26. 1 annex i summary of product characteristics - Xtandi, INN-enzalutamide, accessed July 11, 2025, https://ec.europa.eu/health/documents/community-register/2021/20210617151930/anx_151930_en.pdf
27. Xtandi (enzalutamide) dosing, indications, interactions, adverse effects, and more, accessed July 11, 2025, https://reference.medscape.com/drug/xtandi-enzalutamide-999769
28. Enzalutamide reduces morbidities associated with bone metastases in men with mCRPC, accessed July 11, 2025, https://ecancer.org/en/news/6293-enzalutamide-reduces-morbidities-associated-with-bone-metastases-in-men-with-mcrpc
29. Clinical Trial Results | XTANDI® (enzalutamide), accessed July 11, 2025, https://www.xtandi.com/clinical-trials
30. XTANDI® (enzalutamide) Drug Information Publications | HCP Site, accessed July 11, 2025, https://www.xtandihcp.com/efficacy/publications
31. Enzalutamide Helps Extend Life for Men with Advanced Prostate Cancer | Duke Health, accessed July 11, 2025, https://corporate.dukehealth.org/news/enzalutamide-helps-extend-life-men-advanced-prostate-cancer
32. Study Details | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | ClinicalTrials.gov, accessed July 11, 2025, https://www.clinicaltrials.gov/study/NCT02446405
33. ENZAMET - ANZUP, accessed July 11, 2025, https://anzup.org.au/clinical-trial/enzamet-trial/
34. 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5090
35. Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). | Request PDF - ResearchGate, accessed July 11, 2025, https://www.researchgate.net/publication/367689808_Updated_overall_survival_outcomes_in_ENZAMET_ANZUP_1304_an_international_cooperative_group_trial_of_enzalutamide_in_metastatic_hormone-sensitive_prostate_cancer_mHSPC
36. ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - UroToday, accessed July 11, 2025, https://www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137646-asco-2022-updated-overall-survival-outcomes-in-enzamet-anzup-1304-an-international-cooperative-group-trial-of-enzalutamide-in-metastatic-hormone-sensitive-prostate-cancer-mhspc.html
37. XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence - Investing News Network, accessed July 11, 2025, https://investingnews.com/xtandi-r-plus-leuprolide-significantly-improves-survival-outcomes-in-men-with-non-metastatic-hormone-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence/
38. XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence | Seeking Alpha, accessed July 11, 2025, https://seekingalpha.com/pr/20161696-xtandi-plus-leuprolide-significantly-improves-survival-outcomes-in-men-with-non-metastatic
39. Xtandi Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 11, 2025, https://www.drugs.com/sfx/xtandi-side-effects.html
40. Enzalutamide Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 11, 2025, https://www.drugs.com/dosage/enzalutamide.html
41. Xtandi: Mild to serious side effects and how to manage them - MedicalNewsToday, accessed July 11, 2025, https://www.medicalnewstoday.com/articles/drugs-xtandi-side-effects
42. Enzalutamide (oral route) - Mayo Clinic, accessed July 11, 2025, https://www.mayoclinic.org/drugs-supplements/enzalutamide-oral-route/description/drg-20075790
43. Abstract 16180: Cardiovascular Adverse Events Associated With Androgen Receptor-targeted Therapy Used in the Treatment of Prostate Cancer | Circulation, accessed July 11, 2025, https://www.ahajournals.org/doi/10.1161/circ.142.suppl_3.16180
44. The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer - PubMed, accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/29339044/
45. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer - PubMed Central, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9360470/
46. Risk of heart failure with abiraterone versus enzalutamide amongst patients diagnosed with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e24029
47. Real-world comparative effectiveness and cardiovascular safety of enzalutamide versus abiraterone amongst older men diagnosed with metastatic castration-resistant prostate cancer. - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5053
48. Retrospective analysis of fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide. | Journal of Clinical Oncology - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2018.36.6_suppl.374
49. Enzalutamide | Macmillan Cancer Support, accessed July 11, 2025, https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/enzalutamide
50. Side Effects | XTANDI® (enzalutamide), accessed July 11, 2025, https://www.xtandi.com/side-effects
51. Mitigating the impacts of ADT-induced fatigue in prostate cancer - YouTube, accessed July 11, 2025, https://www.youtube.com/watch?v=ETT4D4mXNMI
52. The effect of a reduced dose of enzalutamide on fatigue and cognition. - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5051
53. The effect of a reduced dose of enzalutamide on fatigue and cognition. - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.5051
54. The Importance of Bone-Protecting Agents When Treating Advanced Prostate Cancer, accessed July 11, 2025, https://www.urotoday.com/newsletter-archive/listid-14/mailid-10054-the-importance-of-bone-protecting-agents-when-treating-advanced-prostate-cancer.html
55. Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results. | Journal of Clinical Oncology - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2017.35.6_suppl.220
56. Breast swelling (gynaecomastia) | Prostate cancer, accessed July 11, 2025, https://www.cancerresearchuk.org/about-cancer/prostate-cancer/practical-emotional-support/hormone-symptoms/breast-swelling-gynaecomastia
57. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7305090/
58. Gynecomastia in Patients with Prostate Cancer: A Systematic Review | PLOS One, accessed July 11, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136094
59. Managing Gynecomastia in ARPI Prostate Cancer Treatment "Presentation" - Neal Shore, accessed July 11, 2025, https://www.urotoday.com/video-lectures/apccc-2024-conference-presentations-videos/video/4464-managing-gynecomastia-in-arpi-prostate-cancer-treatment-presentation-neal-shore.html
60. Enzalutamide Patient Handout - BC Cancer, accessed July 11, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Enzalutamide_handout.pdf
61. XTANDI is taken as 160 mg orally, once daily - Xtandi HCP, accessed July 11, 2025, https://www.xtandihcp.com/files/dosing-card.pdf
62. Enzalutamide: Understanding and Managing Drug Interactions to Improve Patient Safety and Drug Efficacy - PubMed Central, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11182822/
63. XTANDI® (enzalutamide) capsules, for oral use - Pfizer, accessed July 11, 2025, https://www.pfizer.com/products/product-detail/xtandi_enzalutamide_capsules_for_oral_use
64. Legal Notice | XTANDI® (enzalutamide), accessed July 11, 2025, https://www.xtandi.com/legal-notice
65. Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p) - ClinicalTrials.gov, accessed July 11, 2025, https://clinicaltrials.gov/study/NCT04419402
66. ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). - ResearchGate, accessed July 11, 2025, https://www.researchgate.net/publication/349741820_ENZA-p_A_randomized_phase_II_trial_using_PSMA_as_a_therapeutic_agent_and_prognostic_indicator_in_men_with_metastatic_castration-resistant_prostate_cancer_treated_with_enzalutamide_ANZUP_1901
67. Combining [177Lu]Lu-PSMA-617 and enzalutamide in metastatic castration-resistant prostate cancer: promising but with caveats for now - AME Clinical Trials Review, accessed July 11, 2025, https://actr.amegroups.org/article/view/10213/html
68. ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901) - ResearchGate, accessed July 11, 2025, https://www.researchgate.net/publication/351815164_ENZA-p_trial_protocol_a_randomized_phase_II_trial_using_prostate-specific_membrane_antigen_as_a_therapeutic_target_and_prognostic_indicator_in_men_with_metastatic_castration-resistant_prostate_cancer_
69. Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett, accessed July 11, 2025, https://www.urotoday.com/video-lectures/asco-gu-2025/video/4660-phase-ii-enza-p-trial-explores-effect-of-lutetium-psma-with-enzalutamide-louise-emmett.html
70. FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | ClinicalTrials.gov, accessed July 11, 2025, https://www.clinicaltrials.gov/ct2/show/NCT05011188
71. UCSF Metastatic Castration-Resistant Prostate Cancer Clinical Trials — San Francisco Bay Area, accessed July 11, 2025, https://clinicaltrials.ucsf.edu/metastatic-castration-resistant-prostate
72. FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting, accessed July 11, 2025, https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-presentation-positive-interim-data-phase-1b
73. FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer, accessed July 11, 2025, https://clin.larvol.com/trial-detail/NCT05011188
74. A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) - ClinicalTrials.gov, accessed July 11, 2025, https://clinicaltrials.gov/study/NCT02799745
75. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial - PubMed Central, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9204619/
76. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial - PubMed, accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/35708696/
77. Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | ClinicalTrials.gov, accessed July 11, 2025, https://clinicaltrials.gov/study/NCT01889238